Researchers developing drug to combat west nile virus, other related viruses

June 8, 2012

(Medical Xpress) -- Professors at Colorado State University and the University of Northern Colorado are developing a drug that can stop replication of West Nile, dengue and yellow fever viruses that continue to plague two-thirds of the world's population with no clinically useful antiviral drugs available.

The research of Brian Geiss, Assistant Professor in the Department of Microbiology, and Pathology and Susan Keenan, Associate Professor and Director of the School of at the University of Northern Colorado, appears this week online in the peer-reviewed .

West Nile and dengue fever are vector-borne – pathogens that can be transferred from an insect to a human - in a family of viruses known as the flaviviruses. The National Institutes of Health considers a number of flaviviruses priority pathogens because they cause life-threatening illness with few drugs or vaccines available and have the potential to be used as biological weapons.

More than two billion people are at risk globally of infection by dengue virus, and virus is endemic in 47 of the 48 lower United States. Dengue virus has re-emerged in southern Florida and Hawaii over the past few years. Worldwide, as many as 50 million infections occur each year causing roughly 20,000 to 30,000 deaths.

Geiss and Keenan are developing a drug that can bind to a protein critical for viral replication and block the protein’s function. The viral protein forms a structure on the genome called a “cap” that helps the virus make its replication proteins and protects the viral genome from being degraded in cells. Without this cap structure the virus can’t make the proteins it needs to replicate and the viral genome will be destroyed by the cell.

The researchers screened large chemical libraries for molecules that inhibited this enzyme, then used computer modeling to identify molecules that were better able to bind the viral protein. One of the molecules they found was able to reduce virus replication in cells by more than 1,000-fold.

More work is ahead to improve the effectiveness of the drug now that they’ve confirmed it works in cells against several different viruses, Geiss said. Geiss and Keenan have filed a provisional patent with CSU Ventures to commercialize the technology.

“We’re in the process of testing these drugs against a number of different flaviviruses and trying to improve how well it works in animal models, so there’s a lot more work to get it to the point where it would be used as an investigational new drug,” Geiss said. “However, this is an exciting new finding that has the potential to reduce the suffering caused by these serious pathogens.”

Geiss’ and Keenan’s research is supported by the Rocky Mountain Regional Center of Excellence at Colorado State University – one of only 10 NIH supported centers nationwide aimed at developing novel therapeutics and diagnostics against emerging infectious diseases.

Explore further: Androgen boosts hepatitis B virus replication

Related Stories

Androgen boosts hepatitis B virus replication

February 16, 2012
Androgen enhances replication of hepatitis B virus (HBV), rendering males more vulnerable than females to this virus, according to research published in the February Journal of Virology.

Researchers identify new cell that attacks dengue virus

May 16, 2011
Mast cells, which can help the body respond to bacteria and pathogens, also apparently sound the alarm around viruses delivered by a mosquito bite, according to researchers at Duke-NUS Graduate Medical School in Singapore.

Recommended for you

Engineered protein treatment found to reduce obesity in mice, rats and primates

October 19, 2017
(Medical Xpress)—A team of researchers with pharmaceutical company Amgen Inc. report that an engineered version of a protein naturally found in the body caused test mice, rats and cynomolgus monkeys to lose weight. In their ...

New procedure enables cultivation of human brain sections in the petri dish

October 19, 2017
Researchers at the University of Tübingen have become the first to keep human brain tissue alive outside the body for several weeks. The researchers, headed by Dr. Niklas Schwarz, Dr. Henner Koch and Dr. Thomas Wuttke at ...

Cancer drug found to offer promising results in treating sepsis in test mice

October 19, 2017
(Medical Xpress)—A combined team of researchers from China and the U.S. has found that a drug commonly used to treat lung cancer in humans offers a degree of protection against sepsis in test mice. In their paper published ...

Tracing cell death pathway points to drug targets for brain damage, kidney injury, asthma

October 19, 2017
University of Pittsburgh scientists are unlocking the complexities of a recently discovered cell death process that plays a key role in health and disease, and new findings link their discovery to asthma, kidney injury and ...

Study reveals key molecular link in major cell growth pathway

October 19, 2017
A team of scientists led by Whitehead Institute has uncovered a surprising molecular link that connects how cells regulate growth with how they sense and make available the nutrients required for growth. Their work, which ...

Inflammation trains the skin to heal faster

October 18, 2017
Scars may fade, but the skin remembers. New research from The Rockefeller University reveals that wounds or other harmful, inflammation-provoking experiences impart long-lasting memories to stem cells residing in the skin, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.